Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late Breaking Clinical Trial ...
SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that the successful ...
Elixir Pharmaceuticals Inc., a Cambridge, Mass.-based drug company focused on metabolic diseases like diabetes and obesity, has withdrawn registration for an $86.25 million IPO, due to “market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results